Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8019790 | 0.78 | PLG (0.31) | — | |
| SCHEMBL30859305 | 0.74 | CTSK (0.30) | CTSKUSP2SMN1; SMN2 | |
| SCHEMBL3525539 | 0.74 | SMN1; SMN2 (0.43) | SMN1; SMN2 | |
| SCHEMBL16234619 | 0.73 | CYP3A4 (0.42) | CYP4F2CYP4A11CTSKSMN1; SMN2 | |
| SCHEMBL22927448 | 0.71 | DGAT1 (0.33) | CYP4F2CYP4A11CTSKUSP2SMN1; SMN2 | |
| SCHEMBL7435411 | 0.70 | SMN1; SMN2 (0.40) | SMN1; SMN2 | |
| SCHEMBL9123239 | 0.70 | CTSK (0.33) | CTSKUSP2SMN1; SMN2 | |
| SCHEMBL22098422 | 0.70 | CYP4F2 (0.44) | CYP4F2CYP4A11 | |
| SCHEMBL28535485 | 0.70 | CTSK (0.31) | CYP4F2CYP4A11CTSK | |
| SCHEMBL571145 | 0.70 | CTSK (0.35) | CTSKSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-08-28 | — | — | US | disclosed |
| WO-2008095058-A1 | HCV PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO. LTD. (TW) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207528-A1 | Administering derivatives of 4-(3-pyrrolidinyloxy)quinoline | GLS2, SLC10A1, UGT1A1 | CYP4F2 8/4885CYP4A11 58/4885CTSK 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.